The short and distort raid has lost all it's punch and once again fundamentals will be the driver of the share price. We should get the July numbers on the 6th, 7th or 8th of this month which will demonstrate continued growth trends in m/s and n/s.
Whether you look at growth rates, gross and op margins or a forward P/E that is under 10, this is a screaming buy at these levels.
There are no bio similiars, generics or any other competition to change our sales trends as the shorts would like the retailer to believe. Insurance companies are covering the cost of the drug and we have new indications that we have yet to penetrated.
We are either at the bottom of the correction, or the bottom will be made when the scrip data is released.
Funny we are talking about QCOR's growth slowing down and what the impact would be on pps when the current valuation at 10 forward P/E is already assuming no growth. That's lower than the P/E of Pfizer, a company that is shrinking dramatically, or the P/E of HDD manufacturers or coal companies, industries with a risk of secular decline. It is 30% lower than the S&P500 for crying out loud. Unless you believe Citron's thesis of the drug being snake oil and generics being around the corner (Biosim anyone?), QCOR's current valuation is a gift. But the market can be irrational for quote a long time so I don't expect big movements. I hope to be back in the 50s after Q4 results are reported.
I added a few days ago but my gut tells me that we will have to wait a while before we see mid 40's again. Too many weak hands out there who keep selling the rallies. I got in now in case I am wrong (which I could very well be) and the stock takes off soon.
Now, we could get a "Citron investigated" rally but absent that, I think we wait it out and reap the money in at a later time.